The place of mycophenolate mofetil in glomerular diseases;Place du mycophénolate mofétil dans les glomé rulopathies

Presse Medicale

Volumn 32, Issue 27, 2003, Pages 1277-1282

  Badid, Chérif ^a   Babici, D ^b   Laville, M ^b  

^a BICHAT HOSPITAL   (France)

^b EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; GLOMERULONEPHRITIS; GLOMERULOPATHY; GLYCOSYLATION; GRAFT REJECTION; HUMAN; INFECTION; INHIBITION KINETICS; LEUKOPENIA; LUNG DISEASE; LYMPHOCYTE PROLIFERATION; PANCREATITIS; PROTEIN EXPRESSION; REVIEW;

CLINICAL TRIALS; ENZYME INHIBITORS; HUMANS; KIDNEY GLOMERULUS; MYCOPHENOLIC ACID; NEPHRITIS;

EID: 0041819561     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Eugui EM, Mirkovitch A, Allison AC. Lymphocyte-selective antiproliferative and immunosuppressive effects of mycophenolic acid in mice. Scand J Immunol 1991; 33; 175-83.
2. Sintchak M, Fleming MA, Futer O et al. Structure and mechanisms of inosine monophosphate deshydrogenase in complex with the immunosuppressant mycophenolic acid. Cell 1996; 85: 921-30.
3. Allison AC, Kowalski WJ, Muller O, Walters RV, Eugui EM. Mycophenolic acid and brequinar, inhibitors of purine and pyrimidine synthesis, block the glycosylation of adhesion molecules. Transplant Proc 1993; 25: 67-70.
4. European Mycophenolate Mofetil cooperative study group: Placebo-controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection. Lancet 1995; 345: 1321-5.
5. Weir MR, Ward MT, Blahut SA et al. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy. Kidney Int 2001; 59: 1567-73.
6. Thervet E, Socié G. Perspectives des nouveaux immunosuppresseurs en greffe de moelle et pour le traitement des maladies auto-immunes. Hématologie 1999; 5: 494-501.
7. Thervet E, Anglicheau D, Legendre C. Pharmacologie du mycophénolate mofétil: données récentes et conséquences cliniques. Néphrologie 2001; 22: 331-7.
8. Hauser IA, Renders L, Radeke HH, Sterzel RB, Goppelte-Struebe M. Mycophenolate inhibits rat and human mesangial cells by guanosine depletion. Nephrol Dial Transplant 1999; 14: 58-63.
9. Smith KGC, Isbel NM, Catton MG, Leydon JA, Becker GJ, Walker RG. Suppression of the humoral immune response by mycophenolate mofetil. Nephrol Dial Transplant 1998; 13: 160-4.
10. Kimball JA, Pescovitz MD, Book BK, Norman DJ. Reduced human IgG anti-ATGAM antibody formation in renal transplant recipients receiving mycophenolate mofetil. Transplantation 1995; 60: 1379-83.
11. Gregory CR, Pratt RE, Huie P et al. Effects of treatment with cyclosporine, FK506, rapamycin, mycophenolic acid or desoxyspergualin on vascular muscle proliferation in vitro and in vivo. Transplant Proc 1993; 25: 770-1
12. Mohacsi PJ, Tuller D, Hulliger B, Wijngaard PU. Different inhibitory effects of immunosuppressive drugs on human and rat aortic smooth muscle and endothelial cell proliferation stimulated by platelet-derived growth factor or endothelial cell growth factor. J Heart Lung Transplant 1997; 16: 484-92.
13. Romero F, Rodriguez-iturbe B, Pons H et al. Mycophenolate mofetil treatment reduces cholesterol-induced atherosclerosis in the rabbit. Atherosclerosis 2000; 152: 127-33.
14. Ojo AO, Meier-Kriesche HU, Hanson JA, et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 2000; 69: 2405-9.
15. Van Bruggen MC, Walgreen B, Rijke TP, Berden JH. Attenuation of murine lupus nephritis by mycophenolate. J Am Soc Nephrol 1998; 9: 1407-15.
16. Zoja C, Benigni A, Noris M et al. Mycophenolate mofetil combined with a cyclooxygenase-2 inhibitor ameliorates murine lupus nephritis. Kidney Int 2001; 60: 653-63.
17. Penny MJ, Boyd RA, Hall BM. Mycophenolate mofetil prevents the induction of active Heymann nephritis: association with Th2 cytokine inhibition. J Am Soc Nephrol 1998; 9: 2272-82.
18. Badid C, Vincent M, Hadj-Aissa A et al. Mycophenolate Mofetil reduces interstitial myofibroblast infiltration and collagen III deposit. Kidney Int 2000; 58: 51-61.
19. Remuzzi G, Zoja C, Gagliardini E, Corna D, Abbate M, Benigni A. Combining an antiproteinuric approach with mycophenolate mofetil fully suppresses progressive nephropathy of experimental animals. J Am Soc Nephrol 1999;10: 1542-9.
20. Fujihara CK, Noronha ID, Malheiros DM, Antunes GR, Braga de Oliveira J, Zatz R. Combined mycophenolate mofetil and losartan therapy arrests established injury in the remnant kidney. J Am Soc Nephrol 2000; 11: 283-290.
21. Miller G, Zimmerman R, Radhakrishnan J, Appel G. Use of mycophenolate mofetil in resistant membranous nephropathy. Am J Kidney Dis 2000; 36: 250-6.
22. Choi MJ, Eustace JA, Gimenez LF et al. Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int 2002; 61: 1098-114.
23. Cross J, Jayne D. Mycophenolate mofetil in lupus nephritis. Lupus 2000; 9: 647-50.
24. Glicklich D, Acharya A. Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cydophosphamide. Am J Kidney Dis 1998; 32:318-22.
25. Briggs WA, Choi MJ, Scheel PJ, Kiberd B, MacDonald A. Successful mycophenolate mofetil treatment of glomerular disease. Am J Kidney Dis 1998; 31: 213-17.
26. Dooley MA, Cosio FG, Nachman PH et al. Mycophenolate mofetil therapy in lupus nephritis: clinical observations. J Am Soc Nephrol 1999; 10: 833-9.
27. Gaubitz M, Schorat A, Schotte H, Kern P, Domschke W. Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial. Lupus 1999; 8: 731-6.
28. Wallman L, Stewart G, Chapman J, O'Connell P, Fulcher D. Mycophenolate mofetil for treatment of refractory lupus nephritis: four pilot cases. Aust NZJ Med 2000; 30: 712-15.
29. Chan TM, Li FK, Tang CSO et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 2000; 343: 1156-62.
30. Kingdon E, Mclean A, Psimenou E, Davenport A, Powis SH, Sweny P, Burns A. The safety and efficacy of MMF in lupus nephritis: a pilot study. Lupus 2001; 10: 606-11.
31. Buratti S, Szer IS, Spencer CH, Bartosh S, Reiff A. Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus. J Rheumatol 2001; 28: 2103-8.
32. Austin HA, Klippel JH, Balow JE et al. Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314: 614-19.
33. Nowack R, Gobel U, Klooker P, Hergesell O, Andrassy K, Vanderwoude FJ. Mycophenolate mofetil for maintenance therapy of wegener granulomatosis and microscopic polyangeitis: A pilot study in 11 patients with renal involvement. J Am Soc Nephrol 1999; 10: 1965-71.
34. Nowack R, Brick R, Van der Woude FJ. Mycophenolate mofetil for systemic vasculitis and IgA nephropathy. Lancet 1997; 349: 774.